Novogene, PacBio to Codevelop Precision Medicine Applications Based on Sequel

Jul 18, 2017 | staff reporter

NEW YORK (GenomeWeb) – Novogene and Pacific Biosciences said today that they plan to co-develop and co-market applications based on PacBio's Sequel system that focus on basic and translational research in precision medicine.

In particular, the firms will focus on methods for sample processing, workflow automation, algorithm development, and database construction.

Financial and other details of the agreement were not disclosed.

Novogene is a sequencing service provider based in Beijing, but also has branches in Hong Kong, the US, and the UK. It operates 10 Sequel systems and has expertise in developing sample preparation, data analysis, and interpretation tools.

Filed under

Clinical Sequencing

Next-Generation Sequencing

single-molecule sequencing

Pacific Biosciences

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.